Legend Biotech (LEGN) 6-K Legend Biotech Corporation Announces Proposed Public Offering

ALL, Acute lymphoblastic leukemia; BCMA, B-cell maturation antigen; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; GPC3, Glypican-3; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; IIT, investigator-initiated trial; NHL, non-Hodgkin lymphomas; MM, multiple myeloma; NSCLC, non small cell lung cancer; SCLC, small cell lung cancer *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. †Phase 1 IIT in China. ‡Multiple allogeneic platforms are being developed. Infectious Diseases Solid Tumors NHL-DLBCL† /ALL† (CD19 x CD20 x CD22) MM* (BCMA) HIV (Undisclosed) LEGEND-2† CARTITUDE-4 Gastric† (Claudin 18.2) Hematologic Malignancies CARTIFAN-1 CARTITUDE-2 Global China US HCC (GPC3) † SCLC (DLL3) CARTITUDE-1 Pancreatic (Claudin 18.2) MM (BCMA)‡ Autologous CARTITUDE-5 Preclinical Phase 1 Phase 2 Phase 3 CARTITUDE-6 NSCLC (GPC3) Exhibit 99.5